4.10.29.2Vertical
Maternal-Fetal Medicine Programs
High-risk obstetrics programs managing complicated pregnancies.
Market snapshot
These figures describe Women's Health & OB/GYN (4.10.29), the segment that Maternal-Fetal Medicine Programs sits within — not Maternal-Fetal Medicine Programs on its own.
- Market size
- ~$4.6B
- Growth
- ~9.2%CAGR (2017–22, nominal)
- Companies
- ~2,700
FragmentationConsolidatingEstimate
U.S. Census Bureau 2022 CBP/Economic Census, NAICS 621410 (Family Planning Centers) — a small slice; most OB/GYN care sits within physician offices (621111).
Business model & economics
Revenue model
Reimbursed OB/GYN care plus cash-pay fertility
Key economics
- Recurring revenue
- Moderate
- EBITDA margin
- 15–25%; fertility higher
- Capex intensity
- Moderate
recurring women's-health relationships
Characteristics
- Fertility (IVF) the high-growth, cash-pay sub-segment.
- MSO consolidation of OB/GYN practices.
- Delayed childbearing and awareness drive demand.
M&A deal context
Deal activityHigh
Who’s acquiring
- Women's-health MSO platforms
- Fertility-network consolidators
- PE-backed acquirers
What’s driving deals
- Fertility-network roll-up.
- OB/GYN practice consolidation.
- Cash-pay fertility demand.
Find Maternal-Fetal Medicine Programs acquisition targets
Search Acquisera’s index for companies classified under Maternal-Fetal Medicine Programs (4.10.29.2) and build a targeted deal pipeline.
Search companies